Stockscreener 앱 받기
13.76
2.99%
0.40
시장 영업 전:
13.67
-0.09
-0.65%
전일 마감가:
$13.36
열려 있는:
$13.5
하루 거래량:
754.52K
Relative Volume:
0.88
시가총액:
$883.73M
수익:
$161.10M
순이익/손실:
$-308.60M
주가수익비율:
-2.9465
EPS:
-4.67
순현금흐름:
$-259.90M
1주 성능:
+3.50%
1개월 성능:
+2.76%
6개월 성능:
+80.81%
1년 성능:
-16.71%
1일 변동 폭
$13.29
$13.93
1주일 범위
$12.61
$13.93
52주 변동 폭
$5.90
$18.93
Arvinas Inc Stock (ARVN) Company Profile
명칭
Arvinas Inc
전화
203-535-1456
주소
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
13.76 | 858.04M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-10-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-09-24 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2025-06-02 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | 다운그레이드 | Truist | Buy → Hold |
| 2025-05-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-02 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-12 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-03-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2024-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-01 | 개시 | Goldman | Buy |
| 2023-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-11-20 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-10-23 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-01-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | 개시 | Barclays | Overweight |
| 2022-06-21 | 개시 | Jefferies | Hold |
| 2022-05-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-04-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2022-01-19 | 개시 | Goldman | Buy |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-09 | 개시 | BofA Securities | Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-21 | 개시 | Truist | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-12-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-06-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-12 | 개시 | Oppenheimer | Perform |
| 2019-12-19 | 개시 | H.C. Wainwright | Buy |
| 2019-11-25 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-25 | 개시 | Wedbush | Outperform |
| 2019-09-12 | 개시 | BMO Capital Markets | Outperform |
| 2019-08-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-22 | 개시 | Citigroup | Buy |
| 2018-10-22 | 개시 | Goldman | Neutral |
| 2018-10-22 | 개시 | Piper Jaffray | Overweight |
모두보기
Arvinas Inc 주식(ARVN)의 최신 뉴스
Arbiter Partners Capital Management LLC Invests $3.86 Million in Arvinas, Inc. $ARVN - MarketBeat
Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference - Yahoo Finance
ARVN: Multiple phase I programs advance with key data and commercialization milestones ahead - TradingView
ARVN: Multiple phase 1 programs advance with key data updates expected for LRRK2, BCL6, and KRAS - TradingView
Arvinas (NASDAQ:ARVN) Director John Houston Sells 35,297 Shares - MarketBeat
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials - Insider Monkey
Arvinas (NASDAQ:ARVN) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
TD Cowen Health Care Conference - marketscreener.com
Arvinas Holding Company (ARVN) Gets a Hold from Morgan Stanley - The Globe and Mail
Arvinas, Inc. (ARVN) Stock Analysis: Navigating the 6.50% Upside Potential Amidst Clinical Innovations - DirectorsTalk Interviews
HC Wainwright Estimates Arvinas' Q1 Earnings (NASDAQ:ARVN) - MarketBeat
Arvinas Holding Company (ARVN) Receives a Buy from Wells Fargo - The Globe and Mail
Arvinas outlines 2026 clinical data milestones and maintains cash runway into second half of 2028 amid strategic pipeline focus - MSN
Analysts Conflicted on These Healthcare Names: Akebia Therapeutics (AKBA), Idexx Laboratories (IDXX) and Arvinas Holding Company (ARVN) - The Globe and Mail
New CEO at local biotech firm is leading shift to early-stage drugs - Yale Daily News
Barclays Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN) - The Globe and Mail
Arvinas CSO Cacace sells $43,885 in stock to cover tax obligations - Investing.com Australia
Arvinas chief accounting officer Loomis sells $13k in stock By Investing.com - Investing.com South Africa
Teel Randy, president and CEO of Arvinas, sells $58k in stock By Investing.com - Investing.com Australia
Teel Randy, president and CEO of Arvinas, sells $58k in stock - Investing.com Canada
Arvinas chief accounting officer Loomis sells $13k in stock - Investing.com Australia
Arvinas (NASDAQ:ARVN) CAO David Loomis Sells 1,108 Shares - MarketBeat
Arvinas (NASDAQ:ARVN) CEO Randy Teel Sells 4,786 Shares - MarketBeat
[Form 4] ARVINAS, INC. Insider Trading Activity - Stock Titan
5 Analysts Assess Arvinas: What You Need To Know - Benzinga
Arvinas (NASDAQ:ARVN) Trading Up 9%Still a Buy? - MarketBeat
Arvinas (NASDAQ:ARVN) Receives Overweight Rating from Piper Sandler - MarketBeat
Piper Sandler Raises Price Target on Arvinas (ARVN) to $20.00 | - GuruFocus
ARVN: Evercore ISI Raises Price Target to $19, Maintains Outperf - GuruFocus
Arvinas (ARVN): Wedbush Maintains Neutral Rating and Raises Pric - GuruFocus
Arvinas, Inc. (NASDAQ:ARVN) Q4 2025 Earnings Call Transcript - Insider Monkey
Arvinas (ARVN) Q4 Loss Of US$67.4 Million Reinforces Profitability Concerns - Sahm
Arvinas earnings missed by $0.59, revenue fell short of estimates - Investing.com Australia
Arvinas, Inc. (NASDAQ:ARVN) Given Average Rating of "Hold" by Brokerages - MarketBeat
Arvinas (ARVN) Reports Significant Revenue Decline in Q4 - GuruFocus
Wedbush raises Arvinas stock price target to $11 on pipeline progress By Investing.com - Investing.com South Africa
Wedbush Maintains Neutral on Arvinas, Inc. (ARVN) Feb 24, 2026 - Meyka
ARVINAS, INC. SEC 10-K Report - TradingView
Wedbush raises Arvinas stock price target to $11 on pipeline progress - Investing.com Australia
Arvinas Inc (ARVN) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges with ... By GuruFocus - Investing.com Canada
Arvinas (ARVN) Projects Financial Stability into Late 2028 - GuruFocus
Arvinas Inc (ARVN) Q4 2025 Earnings Call Highlights: Navigating - GuruFocus
Wedbush Lifts Price Target on Arvinas to $11 From $9, Keeps Neutral Rating - marketscreener.com
Arvinas (ARVN) Q4 2025 Earnings Call Transcript - AOL.com
Arvinas Q4 2025 Earnings Call Transcript - MarketBeat
Arvinas, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
ARVN: Strong cash position and pipeline progress set up multiple clinical milestones for 2026 - TradingView
Arvinas Q4 Earnings Call Highlights - MarketBeat
Arvinas (NASDAQ:ARVN) Shares Gap Down After Earnings Miss - MarketBeat
Earnings call transcript: Arvinas Inc. Q4 2025 results miss expectations, stock dips - Investing.com Nigeria
Arvinas (NASDAQ:ARVN) Releases Earnings Results, Misses Expectations By $0.55 EPS - MarketBeat
Arvinas Inc (ARVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):